The Procter & Gamble Company (PG) vs Arcadia Biosciences, Inc. (RKDA)
The same free fields, in the same order, for both companies, so a figure on one line can be read straight across.
This page states measurements and nothing else. It does not rank the two companies, name one of them, or draw a conclusion from the figures.
Data as of Oct 27, 2026, for both companies.
The figures, field by field
A dash means the snapshot carries no figure for that company on that line. A line is dropped only when neither company has it, so a dash beside a figure is a fact about coverage, not about either company.
| PG | RKDA | |
|---|---|---|
| Sector | Consumer Defensive | Consumer Defensive |
| Industry | Household & Personal Products | Packaged Foods |
| Size band | MEGA | NANO |
| Listing | NYSE | Nasdaq CM |
| Country | United States | United States |
| Theme | household-products | non-alcoholic-beverages |
| Price and returns | ||
| Last close | $159.92 | $0.15 |
| Return · 1 week | +2.09% | +4.69% |
| Return · 1 month | +7.31% | −50.71% |
| Return · 3 months | +7.42% | −75.90% |
| Return · year to date | +14.44% | −92.94% |
| Return · 1 year | +6.94% | −96.20% |
| Distance from the 52-week highThe last close measured against the highest close of the past 52 weeks. | −4.38% | −96.82% |
| 52-week high | $167.25 | $4.78 |
| 52-week low | $137.62 | $0.11 |
| Size and turnover | ||
| Market value · USDConverted to US dollars, so two companies listed in different currencies sit under one heading. | $370.66B | $389.33K |
| Turnover · median day, USDThe median value traded in a session over the past 50 sessions. | $1.29B | $23.50K |
| Employees | 104,000 | 8 |
| Valuation | ||
| Price to earnings · trailing | 24.07× | n/a (negative earnings) |
| Price to earnings · forward | 21.56× | n/a (negative forward earnings) |
| Price to sales | 4.26× | 0.08× |
| Price to book | 6.94× | 0.57× |
| Enterprise value to EBITDA | 16.02× | n/a (negative enterprise value and EBITDA) |
| Enterprise value to revenue | 4.56× | n/a (negative enterprise value) |
| PEG ratio | 4.08 | — |
| Earnings per share · trailing | 6.62 | -4.55 |
| Profitability | ||
| Gross margin | 50.18% | 34.60% |
| Operating margin | 22.08% | −34.37% |
| Profit margin | 18.10% | −234.53% |
| Return on equity | 30.29% | −430.93% |
| Return on assets | 10.72% | −34.76% |
| Growth | ||
| Revenue growth | +1.50% | −0.80% |
| Earnings growth | −15.50% | — |
| Balance sheet and payout | ||
| Debt / equity (%) | 64.49 | — |
| Current ratio | 0.68 | 3.49 |
| Dividend yield | 2.73% | 0.00% |
| Payout ratio | 64.33% | 0.00% |
| Trend and volatility | ||
| RSI · 14 | 61.34 | 22.02 |
| ADX · 14 | 34.41 | 23.30 |
| 50-day average | $148.67 | $0.38 |
| 200-day average | $148.61 | $1.08 |
| Average true range · share of priceAverage true range over 14 sessions, stated as a share of the last close, so it can be read across two share prices. | 2.07% | 23.30% |
The full PG analysis
Everything this table leaves out for The Procter & Gamble Company: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the PG argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full PG analysisThe full RKDA analysis
Everything this table leaves out for Arcadia Biosciences, Inc.: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the RKDA argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full RKDA analysis